Beyond the Standard Lipid Panel: How HeartIQ Score Uses Advanced Biomarkers for Heart Risk Assessment

For decades, we relied on a very simple formula to check our heart health – checking our cholesterol levels and measuring blood pressure. Here is the reality: nearly half of all heart attacks occur in people way before they notice any anomalies.

Standard blood tests only show a part of the larger picture. HeartIQ Score takes a multidimensional approach to preventive cardiology by combining core vitals, advanced lipid profiling, genetic flags, and kidney-metabolic health into one comprehensive profile. Let’s look at the specific metrics that HeartIQ tracks and how they work together to protect your cardiovascular system.

1. Lipid particle analysis

Traditional tests measure the weight of cholesterol in your blood, but HeartIQ analyzes the particle counts and balance to assess true arterial risk. By measuring advanced biomarkers, HeartIQ captures vital information about your inherited cardiovascular risk, hidden inflammation and metabolic profile to make a better assessment of your health.

Apolipoprotein B (Apo B): Every single plaque-causing particle in your bloodstream (LDL, VLDL and IDL) carries exactly one Apo B molecule. Measuring Apo B therefore helps estimate the potential plaque-forming particles on your arterial highway, making it a far more accurate predictor of heart disease than standard LDL cholesterol alone [1].

LDL cholesterol measures the amount of cholesterol carried by LDL particles, whereas ApoB helps estimate the number of atherogenic particles circulating in the blood. When these measures differ, particularly in people with elevated triglycerides or metabolic conditions, ApoB can provide additional information to help clinicians assess cardiovascular risk [5].

Apolipoprotein A1 (Apo A1): Apo A1 is the primary protein component of HDL (“good”) cholesterol, responsible for clearing excess cholesterol from arterial walls and carrying it back to the liver [1].

Apo B / Apo A1 ratio: By evaluating the ratio of damaging Apo B particles to protective Apo A1 particles, HeartIQ can measure the balance between plaque buildup and plaque clearance [2].

Standard lipid panel (HDL, LDL, VLDL, triglycerides, total cholesterol): Provides the foundational baseline of total lipid volume and circulating fats in your blood.

2. Underlying threats & genetic flags

Heart disease risk is often inherited or driven by vascular inflammation, aspects that standard cholesterol panels may not capture.

Lipoprotein(a) [Lp(a)]: Often called the “silent genetic risk factor,” high Lp(a) is an inherited trait that accelerates arterial clotting and plaque formation regardless of diet or lifestyle. HeartIQ flags high Lp(a) early so preventive measures can be put in place [3].

hs-CRP (high-sensitivity C-reactive protein): Elevated hs-CRP signals systemic inflammation in the vascular lining, which can make arterial plaques unstable and prone to rupturing [3].

3. Metabolic & kidney integration

Your heart does not work in isolation. Metabolic health and kidney function directly influence arterial strain.

HbA1c: It measures average blood glucose over the past 3 months. Chronic elevation damages the delicate inner lining of blood vessels (the endothelium), making it easier for Apo B particles to stick and build plaque [4].

Creatinine (serum): It can present an overall picture of kidney function. Early kidney strain or impaired filtration increases strain on the blood vessels. Chronic kidney issues are an independent risk factor in cardiac health.

4. Real-time cardiovascular vitals

Blood pressure & pulse rate: Resting blood pressure and heart rate provide immediate data and overall health status.

Rather than some numbers on a page, HeartIQ transforms static lab results into a personalized, proactive roadmap of prevention.

Once your results are ready, our doctors can guide you through your personalized report, right from the comfort of your home. You can also take control of your cardiac health today with a simple sign up at www.heartiqscore.com.

References

1. Parish S., et al. (2009). The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. European Heart Journal, 30(17), 2137–2146. doi:10.1093/eurheartj/ehp221
2. Yusuf S., et al. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364(9438), 937–952. doi:10.1016/S0140-6736(04)17018-9
3. Mayo Clinic. Heart disease: In-depth guide to prevention and management. mayoclinic.org
4. BMC Nephrology. (2013). Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC Nephrol, 14, 151. link.springer.com
5. American Heart Association. (2026). 2026 Guideline on the Management of Dyslipidemia: Top things to know. AHA Professional Heart Daily. professional.heart.org